Safety, Tolerability, and Pharmacokinetics of CG2001 in Chinese Adult Male Subjects With Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled, Single- and Multi-Dose, Phase 1 Clinical Study
January 2026
Studysummary This study found that the novel alcohol-free topical foam CG2001, combining minoxidil and finasteride, was safe and well-tolerated in Chinese males with androgenetic alopecia, with significantly lower systemic exposure to finasteride compared to oral administration, potentially reducing sexual side effects. Our plain-language summary of this paper — not a Tressless recommendation.
This phase I clinical study evaluated the safety, tolerability, and pharmacokinetics of CG2001, a novel isopropyl alcohol-free topical foam combining minoxidil (5%) and finasteride (0.025%–0.1%), in 44 Chinese males with androgenetic alopecia. The study found that CG2001 was safe and well-tolerated, with no serious adverse events reported. Systemic exposure to finasteride was significantly lower than with oral administration, reducing potential systemic sexual side effects. Both minoxidil and finasteride reached steady state after 7 days of use. The alcohol-free formulation and reduced systemic exposure make CG2001 a promising alternative for treating androgenetic alopecia, warranting further clinical development.
